News from janssen-cilag international nv A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

02 Dec, 2017, 09:00 GMT New Analysis Shows High Rates of Skin Clearance as Measured by Absolute PASI in Patients With Moderate to Severe Plaque Psoriasis Treated With Janssen's TREMFYA® (guselkumab)

FOR MEDICAL AND TRADE MEDIA ONLY Absolute PASI analysis from the VOYAGE 1 trial shows a high level of skin responses were maintained through two...


25 Nov, 2016, 12:30 GMT Janssen Submits Application To EMA Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis

Janssen-Cilag International NV (Janssen) announced today the submission of a Marketing Authorisation Application to the European Medicines Agency...


26 Oct, 2015, 08:00 GMT Janssen Receives Positive CHMP Opinion Recommending EDURANT®▼ (rilpivirine) for the Treatment of Adolescents Aged 12 to <18 Years with HIV-1 infection

FOR UK AND EMEA MEDICAL MEDIA ONLY Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use...


09 Sep, 2015, 12:37 BST Janssen Submits Marketing Authorisation Application for Daratumumab for European Patients With Heavily Pre-treated Multiple Myeloma

Janssen-Cilag International NV announced today it has submitted a new Marketing Authorisation Application to the European Medicines Agency (EMA) for...


10 Jul, 2015, 14:32 BST CORRECTION - Janssen-Cilag International NV: Janssen's IMBRUVICA®▼ (ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström's Macroglobulinemia

FOR TRADE AND MEDICAL MEDIA ONLY Ibrutinib now the first EC-approved treatment option available for this rare B-cell lymphoma Janssen-Cilag...


02 Jun, 2015, 19:30 BST Phase 2 Data Show Daratumumab Achieved Overall Response Rate as Single-Agent in Heavily Pre-Treated Multiple Myeloma Patients

FOR UK TRADE AND MEDICAL MEDIA ONLY Results from the Phase 2 MMY2002 trial (Abstract LBA8512) featured in the official press programme of the 51st...


06 Feb, 2015, 08:00 GMT European Commission Approves Additional Indication for VELCADE® (bortezomib) in Mantle Cell Lymphoma

Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved a variation to the terms of the marketing...


19 Dec, 2014, 14:02 GMT Janssen Receives Positive CHMP Opinion Recommending VELCADE® (bortezomib) for use in Mantle Cell Lymphoma

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...


09 Dec, 2014, 08:00 GMT New Follow-Up Data for IMBRUVICA® (ibrutinib) Presented at ASH Show Longer Term Efficacy in Patients with Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma

Data confirms consistency of IMBRUVICA as an effective treatment option for patients with these challenging blood cancers Note: This press release...


01 Dec, 2014, 08:00 GMT Application Submitted to the EMA to Expand the Therapeutic Indication for IMBRUVICA® (ibrutinib) to Include Treatment of Waldenström's Macroglobulinemia

A rare type of B-cell lymphoma for which there are limited treatment options available in Europe Janssen-Cilag International NV (Janssen) announced...


10 Oct, 2014, 11:34 BST Janssen Submits Application Seeking Approval Of STELARA® In European Union For Pediatric Plaque Psoriasis

Janssen-Cilag International NV (Janssen) announced today that a Type II Variation has been filed with the European Medicines Agency seeking approval...


29 Sep, 2014, 07:23 BST CHMP Announces Positive Opinion for REZOLSTA™, a New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir and Cobicistat

CHMP also issues two label extensions for darunavir Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal...


04 Jun, 2014, 12:15 BST European Commission Approves SYLVANT® (siltuximab) as a Treatment for Patients with Multicentric Castleman's Disease (MCD)

First treatment approved for the management of MCD in Europe Janssen-Cilag International NV ("Janssen") announced today that the European Commission...


21 Mar, 2014, 13:32 GMT Siltuximab Receives CHMP Positive Opinion for Use in the Treatment of Multicentric Castleman's Disease, a Very Rare Blood Disorder

Janssen-Cilag International NV ("Janssen") announced today that The Committee for Medical Products for Human Use (CHMP) of The European Medicines...